GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (FRA:12X1) » Definitions » YoY EPS Growth

Anavex Life Sciences (FRA:12X1) YoY EPS Growth : 36.88% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Anavex Life Sciences's YoY EPS Growth for the quarter that ended in Dec. 2023 was 36.88%.

Anavex Life Sciences's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was €-0.10.


Anavex Life Sciences YoY EPS Growth Historical Data

The historical data trend for Anavex Life Sciences's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences YoY EPS Growth Chart

Anavex Life Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.71 22.04 -20.16 -36.38 10.22

Anavex Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.03 -25.20 14.57 32.97 36.88

Anavex Life Sciences YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Anavex Life Sciences's YoY EPS Growth for the fiscal year that ended in Sep. 2023 is calculated as:

YoY EPS Growth (A: Sep. 2023 )
=(Earnings per Share (Diluted) (A: Sep. 2023 )-Earnings per Share (Diluted) (A: Sep. 2022 ))/ | Earnings per Share (Diluted) (A: Sep. 2022 ) |
=(-0.562--0.626)/ | -0.626 |
=10.22 %

Anavex Life Sciences's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EPS Growth (Q: Dec. 2023 )
=(Earnings per Share (Diluted) (Q: Dec. 2023 )-Earnings per Share (Diluted) (Q: Dec. 2022 )) / | Earnings per Share (Diluted) (Q: Dec. 2022 )) |
=(-0.101--0.16)/ | -0.16 |
=36.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anavex Life Sciences YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences (FRA:12X1) Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (FRA:12X1) Headlines

No Headlines